Protalix Biotherapeutics, Inc.

{
  "main_header": {
    "sid": 1243437,
    "name": "Protalix Biotherapeutics, Inc.",
    "stock_name": "Protalix Biotherapeutics, Inc.",
    "full_name": "Protalix Biotherapeutics, Inc.",
    "name_url": "stocks-analysis/protalix-biotherapeutics-inc",
    "exchange": 1,
    "exchangecode": "ASE",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.91",
    "chg": 1.37,
    "chgp": "88.96%",
    "dir": 1,
    "prev_price": "1.54",
    "mcapval": "166.47",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US74365A3095",
    "curr_date": "Feb 05",
    "curr_time": "",
    "bse_nse_vol": "4.87 M",
    "exc_status": "Active",
    "traded_date": "Feb 05, 2026",
    "traded_date_str": "2026 02 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/protalix-biotherapeutics-inc-1243437-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-changes-valuation-grade-from-attractive-to-fair-amid-price-decline-3707918",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtalixBiother_valuationdot_3707918.png",
        "date": "2025-11-17 15:41:01",
        "description": "Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $1.86. Over the past year, the company has outperformed the S&P 500, achieving a return of 31.91%. Key financial metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%."
      },
      {
        "title": "Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-valuation-grade-downgraded-from-very-attractive-to-attractive-3686322",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtalixBiother_valuationdot_3686322.png",
        "date": "2025-11-10 16:13:49",
        "description": "Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%."
      }
    ],
    "total": 14,
    "sid": "1243437",
    "stock_news_url": "https://www.marketsmojo.com/news/protalix-biotherapeutics-inc-1243437"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape

2025-11-17 15:41:01

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $1.86. Over the past year, the company has outperformed the S&P 500, achieving a return of 31.91%. Key financial metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Read full news article

Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance

2025-11-10 16:13:49

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Read full news article

View All News